Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioMérieux       FR0010096479

BIOMÉRIEUX
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

BIOMERIEUX : Detection of Schmallenberg virus made possible by bioMérieux: the ADIAGENE PCR kit has been validated by ANSES

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/28/2012 | 06:50pm CEST

Detection of Schmallenberg virus made possible by bioMérieux: the ADIAGENE PCR kit has been validated by ANSES

Marcy l'Etoile, France - March 27, 2012. ADIAGENE, a member of the bioMérieux group and specialized in diagnostics for animal health, has obtained ANSES validation for a kit for the detection of Schmallenberg virus, responsible for the epidemic currently affecting livestock in Europe. Based on molecular biology techniques, the new ADIAVET™ Schmallenberg virus PCR detection kit was developed by ADIAGENE in close collaboration with the French Agency for Food, Environmental and Occupational Health and Safety (ANSES, Maisons-Alfort, France). The Direction Générale de l'Alimentation (DGAL) has just authorized its use in certified French public veterinary laboratories.

distributed by

This press release was issued by BioMérieux SA and was initially posted at http://www.biomerieux.com/servlet/srt/bio/portail/dynPage?open=PRT_NWS_REL&doc=PRT_NWS_REL_G_PRS_RLS _269 . It was distributed, unedited and unaltered, by noodls on 2012-03-28 18:43:26 PM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOMÉRIEUX
06/12BIOMERIEUX : NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in Acute Dialysi..
PU
06/05BIOMÉRIEUX : Ex-dividend day for final dividend
FA
05/22BIOMERIEUX : 65-- Bacterial ID and Susceptibility Testing for VISN 2 Downstate
AQ
05/14Culture Media Market Forecast 2025 by Major Players such as Thermo Fisher Sci..
AQ
05/11Culture Media Market Forecast 2025 by Major Players such as Thermo Fisher Sci..
AQ
05/02BIOMERIEUX : NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in Groundbreaking..
PU
04/23BIOMERIEUX : bioMérieux and the University of Antwerp award scholarships to thre..
PU
04/23BIOMERIEUX : bioMérieux and the University of Antwerp award scholarships to thre..
PU
04/19BIOMERIEUX SA : 1st quarter earnings
CO
04/16BIOMERIEUX SA : quaterly sales release
More news
News from SeekingAlpha
2017Biomerieux 69 Marcy L'Etoile reports 1H results 
2016Biomerieux 69 Marcy L'Etoile reports 1H results 
2016Biomerieux 69 Marcy L'Etoile reports Q2 results 
2016Spin-out from bioMerieux secures $32M capital raise 
2015BioMerieux Q2 sales up 18%; sees 2015 top-line growth of 4.5 - 6.5% 
Financials (€)
Sales 2018 2 416 M
EBIT 2018 339 M
Net income 2018 234 M
Debt 2018 93,2 M
Yield 2018 0,48%
P/E ratio 2018 41,54
P/E ratio 2019 35,78
EV / Sales 2018 3,99x
EV / Sales 2019 3,63x
Capitalization 9 552 M
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | FR0010096479 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus UNDERPERFORM
Number of Analysts 12
Average target price 65,7 €
Spread / Average Target -17%
EPS Revisions
Managers
NameTitle
Alexandre Mérieux Chairman & Chief Executive Officer
Guillaume Bouhours Chief Financial Officer & Executive Vice President
Mark Miller Chief Medical Officer
Jean-Luc Bélingard Director
Michele Palladino Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOMÉRIEUX48.06%11 103
BIOMÉRIEUX5.77%11 103
DIASORIN SPA24.73%6 027
AUTOBIO DIAGNOSTICS CO LTD44.29%5 002
MACCURA BIOTECHNOLOGY CO LTD--.--%2 125
SIEGFRIED HOLDING AG23.46%1 711